diclofenac   Click here for help

GtoPdb Ligand ID: 2714

Synonyms: Cataflam® | CGP-45840B | GP-45840 | Voltaren® | Voltarol®
Approved drug PDB Ligand Immunopharmacology Ligand
diclofenac is an approved drug (FDA (1988))
Compound class: Synthetic organic
Comment: Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID)
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: diclofenac

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 49.33
Molecular weight 295.02
XLogP 3.9
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl
Isomeric SMILES OC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl
InChI InChI=1S/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)
InChI Key DCOPUUMXTXDBNB-UHFFFAOYSA-N
Selectivity at ion channels
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
TRPM3 Hs Channel blocker - 5.2 pIC50 - 4
pIC50 5.2 [4]
ASIC3 Hs Channel blocker - 4.0 pIC50 - 5
pIC50 4.0 (IC50 9.2x10-5 M) sustained component [5]
Selectivity at nuclear hormone receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Peroxisome proliferator-activated receptor-γ Hs Antagonist Antagonist 6.2 pKi - 1
pKi 6.2 [1]
Peroxisome proliferator-activated receptor-γ ? Agonist Partial agonist - - - 3
[3]
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
COX-1 Primary target of this compound Hs Inhibitor Inhibition 7.9 pIC50 - 6
pIC50 7.9 (IC50 1.2x10-8 M) [6]
COX-2 Primary target of this compound Hs Inhibitor Inhibition 7.7 pIC50 - 2
pIC50 7.7 (IC50 2x10-8 M) [2]